Drug Trial Radar · NCT00430625
A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease
Last checked: Nov 19, 2026Latest source record: Jun 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Feb 15, 2007
Primary completion
Apr 1, 2009
Study completion Apr 1, 2009
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Feb 2, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to this deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this study is to evaluate the efficacy of every other week dosing of Gene-Activated® Human Glucocerebrosidase (GA-GCB, velaglucerase alfa) at doses of 45 and 60 U/kg in treatment-naïve patients with type 1 Gaucher disease.
Conditions
- Gaucher Disease, Type 1
Interventions
VPRIV ®,Biological
Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group.Time frame: Week 53
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
Hipolito Yrigoyen
Buenos Aires, Argentina
Shaare Zedek Medical Center
Jerusalem, Israel
Sociedad Espanola de Socorros Mutuos
Asunción, Paraguay
National Research Center for Haematology
Moscow, Russia
La Rabta Hospital
Tunis, Tunisia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.